Paraoxanase and Apolipoprotein B in Hypertensive Patients

Hypertension is the most important public health problem and is also quantitatively the most important risk factor for premature cardiovascular diseases, ischemic heart diseases globally. Hypertension alone is a major cause of atherosclerosis that leads to heart attacks and strokes. Apolipoprotein B (Apo B) is a component of chylomicrons and LDL-Cholesterol which are associated with the development of atherosclerosis. Human serum paraoxanase1 (PON1) is an enzyme that is bound to high-density lipoproteins (HDL). It plays a key role in protecting this lipoprotein and biological membrane against oxidative damage. PON1 is hypothesized to be an indicator of the risk of atherosclerosis and coronary artery disease development. Institutional Ethics Committee permission was obtained for carrying out this study. Total of 136 subjects were included in this study and after obtaining written consent, 4 ml of venous blood was collected and used for the estimation Of Apo B, PON1. Serum Apo B was measured by standard traceable assay, Serum PON1 measured spectrophotometry method. The exclusion Criteria were: alcoholic, smoker, pregnancy, any chronic disorder, liver and renal dysfunction. The inclusion criteria for cases: patients with history of HTN and for controls were: age matched healthy volunteers. The results showed that APO B (p = 0.000*) was significantly increased and serum PON1 activity (p = 0.002*) was significantly decreased in hypertensive patients when compared with that of controls respectively. Both Apo B and PON1 have a potential to be a prognostic parameters and may help in management of hypertension.